KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Equity Ratio (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Equity Ratio for 13 consecutive years, with 0.92 as the latest value for Q4 2025.

  • On a quarterly basis, Equity Ratio fell 2.86% to 0.92 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.92, a 2.86% decrease, with the full-year FY2025 number at 0.92, down 2.86% from a year prior.
  • Equity Ratio was 0.92 for Q4 2025 at Xenon Pharmaceuticals, roughly flat from 0.92 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.97 in Q2 2022 to a low of 0.92 in Q4 2025.
  • A 5-year average of 0.95 and a median of 0.95 in 2023 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: rose 19.86% in 2021, then dropped 3.56% in 2025.
  • Xenon Pharmaceuticals' Equity Ratio stood at 0.96 in 2021, then fell by 0.51% to 0.96 in 2022, then rose by 0.53% to 0.96 in 2023, then fell by 1.66% to 0.95 in 2024, then fell by 2.86% to 0.92 in 2025.
  • Per Business Quant, the three most recent readings for XENE's Equity Ratio are 0.92 (Q4 2025), 0.92 (Q3 2025), and 0.94 (Q2 2025).